Indisulam Shows an Anti-Cancer Effect on HPV+ and HPV- Head and Neck Cancer.

ABSTRACT: Background/Objectives: HPV+ head and neck squamous cell carcinoma has been shown to have a unique genomic background, requiring researchers to study it as its own distinct type of cancer. HPV+ tumors have been shown to exhibit fewer genetic mutations in cancer drivers as opposed to their HPV- counterparts. In this paper, we explored how targeting post-transcriptional changes, specifically alternative splicing events, could serve as a potential mechanism to treat HPV+ cancer. Methods: Using indisulam, a drug that targets alternative splicing through the degradation of RBM39, we treated various HPV+ and HPV- cell lines and assessed tumor cell viability. We also tested indisulam in vivo to evaluate its effect on tumor volume. Additionally, we analyzed gene expression differences

SUBMITTER: Hosseini TM 

PROVIDER: S-EPMC11987906 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature